Sitagliptin/Metformin Glenmark 50 mg/850 mg Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sitagliptin/metformin glenmark 50 mg/850 mg

glenmark pharmaceuticals s.r.o., Česká republika - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Sitagliptin/Metformin Glenmark 50 mg/1000 mg Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sitagliptin/metformin glenmark 50 mg/1000 mg

glenmark pharmaceuticals s.r.o., Česká republika - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Sipactimet 50 mg/1000 mg filmom obalené tablety Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sipactimet 50 mg/1000 mg filmom obalené tablety

heaton k.s., Česká republika - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Sipactimet 50 mg/850 mg filmom obalené tablety Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sipactimet 50 mg/850 mg filmom obalené tablety

heaton k.s., Česká republika - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Sitagliptin / Metformin hydrochloride Accord Европейский союз - словацкий - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. trojlôžkových kombinovaná liečba) ako doplnok stravy a cvičenia pacientov nedostatočne kontrolované na ich maximálna tolerovaná dávka metformín a sulfonylmocoviny. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Lonamo Duo 50 mg/1 000 mg Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

lonamo duo 50 mg/1 000 mg

egis pharmaceuticals plc, maďarsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Lonamo Duo 50 mg/850 mg Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

lonamo duo 50 mg/850 mg

egis pharmaceuticals plc, maďarsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)